ARUP Laboratories

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. More about ARUP

In Focus

children testing

ARUP and Seattle Children's Hospital Collaborate on Utilization Management via Seattle Children's PLUGS Program

PLUGS helps pediatric hospital laboratories and practitioners decrease costs and errors associated with unnecessary laboratory testing. ARUP is the first Gold sponsor of this innovative utilization management program.

Read press release.


ARUP Laboratories and PierianDx Create Partnership to Produce More Efficient and Effective Diagnostic Genetic Tests

ARUP will join the PierianDx partner network to share tools, assays, and clinical information to expedite and improve the personalized interpretation of next-generation sequencing clinical diagnostic tests.

Read press release.

free education

Video Lectures for Free CEUs Added Regularly

The following are just two of our many new offerings: Implementing a Test Utilization Management Program by Casey Leavitt, ARUP's director of Consultative Services, and Carrier Detection for Tay-Sachs Disease by Irene De Biase, ARUP's assistant medical director of Biochemical Genetics and Newborn Screening.

View list of all available video lectures.


Ebola Specimen Guidelines

Ebola virus disease, one of numerous viral hemorrhagic fevers, is a severe, often fatal disease in humans and nonhuman primates. Any laboratory testing requested on specimens from suspected Ebola patients should not be sent to ARUP but held until results for Ebola testing are confirmed as negative by the CDC.

Ebola client letter Ebola FAQs and resources

diagnostic innovation

FDA Oversight of LDTs Will Create Negative Effects Across Healthcare

ARUP is a vocal opponent of the FDA's proposed oversight of laboratory-developed tests (LDTs).

ARUP CEO and President Dr. Ashwood responds in Roll Call. AMP voices concern regarding proposed oversight of LDTs. World-renowned medical centers speak out against FDA regulation of LDTs.